Phase II study data suggest that the prostatic acid phosphatase-encoding pTVG-HP vaccine does not improve metastasis-free survival in men with progressive, nonmetastatic, castration-sensitive prostate cancer.
HLA class I evolutionary divergence is associated with response to immune checkpoint inhibitor treatment in people with cancer, show data published in Nature Medicine.
Between 2010 and 2014, more than a third of lung cancer patients in the USA received less intensive treatment than recommended, or indeed no treatment at all, shows an analysis of data from the US National Cancer Database.
Researchers highlight the “almost universal exclusion” of people living with HIV from clinical trials of immune checkpoint inhibitor therapies despite malignancy being the leading cause of morbidity and mortality in this population.
At least half of patients with crizotinib-resistant ALK translocation-positive non-small-cell lung cancer respond to treatment with the new-generation ALK inhibitor ensartinib, including those with brain metastases, phase II study data show.
The reduced prostate cancer risk seen in men with diabetes may be partly explained by detection bias due to a lower biopsy rate following an elevated prostate-specific antigen test result, population-based study data show.